Skip to Content

PEGASUS

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

Patient Information

This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).

More details at: http://clinicaltrials.gov/show/NCT01225562

Study Number
NCT01225562

Clinical Trial Categories

  • Secondary Prevention Trials

Also in this Section